This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Dose Finding Study of KRN125 (Pegfilgrastim) for Treatment of Neutropenic Patients

This study has been completed.
Information provided by (Responsible Party):
Kyowa Hakko Kirin Co., Ltd Identifier:
First received: August 14, 2006
Last updated: February 28, 2017
Last verified: February 2017
To assess the duration of severe neutropenia in cycle 1 of chemotherapy after treatment with a single injection of KRN125 or multiple daily injections of filgrastim.

Condition Intervention Phase
Neutropenia Drug: pegfilgrastim Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Dose Finding Study of KRN125 (Pegfilgrastim) for the Treatment of Chemotherapy - Induced Neutropenia in Malignant Lymphoma

Resource links provided by NLM:

Further study details as provided by Kyowa Hakko Kirin Co., Ltd:

Primary Outcome Measures:
  • To compare the duration of severe neutropenia

Enrollment: 107
Study Start Date: March 2006
Study Completion Date: March 2008
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   20 Years to 74 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • patients diagnosed as malignant lymphoma
  • patients who were refractory to anthracycline or anthraquinone containing chemotherapy
  • patients who are going to receive ESHAP or CHASE treatment regimen
  • ECOG performance status =< 2
  • patients who have appropriate bone marrow, hepatic and renal functions
  • written informed consent

Exclusion Criteria:

  • double cancer
  • history of bone marrow transplantation or PBSCT
  • more than 2 prior chemotherapy regimens
  • primary hematologic disease such as myelodysplastic syndrome
  • previous radiotherapy within 4 weeks of enrollment
  • woman of childbearing potential who were either pregnant, breast feeding
  • patients who participated in other clinical trials within the last 4 weeks of enrollment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00364468

Tokai region
Aichi, Japan
Kyusyu region
Fukuoka, Nagasaki, Japan
Kanto region
Gunma, Saitama, Tokyo, Kanagawa, Japan
Hokkaido region
Hokkaido, Japan
Kinki region
Kyoto, Mie, Shiga, Japan
Tohoku region
Miyagi, Japan
Sponsors and Collaborators
Kyowa Hakko Kirin Co., Ltd
Study Chair: Tomomitsu Hotta, MD Nagoya Medical Center
  More Information

Responsible Party: Kyowa Hakko Kirin Co., Ltd Identifier: NCT00364468     History of Changes
Other Study ID Numbers: KRN125/05-A04
Study First Received: August 14, 2006
Last Updated: February 28, 2017

Keywords provided by Kyowa Hakko Kirin Co., Ltd:
cancer patients

Additional relevant MeSH terms:
Leukocyte Disorders
Hematologic Diseases processed this record on September 20, 2017